ReviewJournal of pharmacokinetics and pharmacodynamics2014
Viral kinetic modeling: state of the art.
Review in Journal of pharmacokinetics and pharmacodynamics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Model-informed drug repurposing: A pharmacometric approach to novel pathogen preparedness, response and retrospection.British journal of clinical pharmacology · 2021Pooled it
- Multiscale Modeling of an 8-Week Combination Regimen of Bemnifosbuvir and Ruzasvir in Patients with Chronic Hepatitis C Virus Infection.Clinical pharmacology and therapeutics · 2026Article
- Bemnifosbuvir: An HCV NS5B Inhibitor With Multiple Modes of Action.Clinical pharmacology and therapeutics · 2026Article
- The architecture of computational antiviralism: a multi-scale framework from molecular targeting to viral ecosystem engineering.Molecular diversity · 2026Review
- Stability of recombinant baculoviruses for biopharmaceutical applications in chemically defined medium.Biotechnology letters · 2026Article
- Spatially structured models of viral dynamics: a scoping review.Microbiology and molecular biology reviews : MMBR · 2025Article
- Review
- Random time-shift approximation enables hierarchical Bayesian inference of mechanistic within-host viral dynamics models on large datasets.PLoS computational biology · 2025Article
- Quantifying Impact of HIV Receptor Surface Density Reveals Differences in Fusion Dynamics of HIV Strains.Viruses · 2025Article
- Multi-objective control to schedule therapies for acute viral infections.Journal of mathematical biology · 2025Article
- Viral and immune dynamics of genital human papillomavirus infections in young women with high temporal resolution.PLoS biology · 2025Observational
- Review
- Using In silico models to predict lymphocyte activation and development in a data rich era.Immunoinformatics (Amsterdam, Netherlands) · 2024Article
- A mathematical model for the within-host (re)infection dynamics of SARS-CoV-2.Mathematical biosciences · 2024Article
- The reproduction number and its probability distribution for stochastic viral dynamics.Journal of the Royal Society, Interface · 2024Article
- Modelling the impact of JNJ-1802, a first-in-class dengue inhibitor blocking the NS3-NS4B interaction, on in-vitro DENV-2 dynamics.PLoS computational biology · 2023Article
- A Novel Mathematical Model That Predicts the Protection Time of SARS-CoV-2 Antibodies.Viruses · 2023Article
- Predicting Influenza A Virus Infection in the Lung from Hematological Data with Machine Learning.mSystems · 2022Article
- Teaching undergraduate physical chemistry lab with kinetic analysis of COVID-19 in the United States.Journal of chemical education · 2022Article
- Antiviral Used among Non-Severe COVID-19 Cases in Relation to Time till Viral Clearance: A Retrospective Cohort Study.Antibiotics (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Viral kinetic (VK) modeling has led to increased understanding of the within host dynamics of viral infections and the effects of therapy. Here we review recent developments in the modeling of viral infection kinetics with emphasis on two infectious diseases: hepatitis C and influenza. We review how VK modeling has evolved from simple models of viral infections treated with a drug or drug cocktail with an assumed constant effectiveness to models that incorporate drug pharmacokinetics and pharmacodynamics, as well as phenomenological models that simply assume drugs have time varying-effectiveness. We also discuss multiscale models that include intracellular events in viral replication, models of drug-resistance, models that include innate and adaptive immune responses and models that incorporate cell-to-cell spread of infection. Overall, VK modeling has provided new insights into the understanding of the disease progression and the modes of action of several drugs. We expect that VK modeling will be increasingly used in the coming years to optimize drug regimens in order to improve therapeutic outcomes and treatment tolerability for infectious diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.